Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression profiling in Prostate cancer cells treated with DOT1L inhibitor

ABSTRACT: We performed expression profiling of prostate cancer cells, LNCaP and PC3 cells that were treated with the specific DOT1L inhibitor EPZ004777 (1uM) for 8 days. We found that unique genes were differentially expressed in both cell lines.

ORGANISM(S): Homo sapiens

PROVIDER: GSE135573 | GEO | 2019/08/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

H3K79me2 ChIP-seq in prostate cancer cells

Project description:We report the application of ChIP sequencing technology for high-throughput profiling of H3K79me2 in prostate cancer cells. We generated genome-wide maps of LNCaP and PC3 cells that were treated with the specific DOT1L inhibitor EPZ004777. We find that lysine 79 dimethylation is sensitive to DOT1L inhibition in both cell lines, however the enrichment of K79 methylated peaks differed between the two cell lines.

2019-08-09 | GSE135574 | GEO

Expression profiling in Prostate cancer cells treated with DOT1L inhibitor

Project description:Expression profiling in Prostate cancer cells treated with DOT1L inhibitor

| PRJNA559347 | ENA

RNA sequencing of CSN5 inhibition in prostate cancer cells

Project description:Human prostate cancer cells treated with shCSN5(sh37) or CSN5 inhibitior (CSN5i-3). Cells were treated with DMSO, 1uM (in C4-2), 5uM (in LNCaP, 22Rv1) or 10 uM (in PC3) CSN5i-3 for 48 hours. Cells were prepared for RNA-seq.

2022-08-17 | GSE173466 | GEO

Research of neopeptides/neoproteins in prostate cancer cell lines

Project description:Validation, by mass spectrometry (MS), of predicted neoantigens in urinary extracellular vesicles coming from cancer prostate patients. We performed MS on PC3, LNCaP and HCT116 cells and compared MS-detected peptides with established PC3 lncRNA peptides, peptides from lncRNAs upregulated in uEVs and Swiss prot databanks.

2022-05-31 | PXD032264 | Pride

Expression Profiling of Mixed Lineage Leukemia Cells Treated with a Potent Small-Molecule DOT1L Inhibitor

Project description:Cell lines bearing MLL translocations (MV4-11 and MOLM-13) were treated with a potent, selective inhibitor of the DOT1L histone methyl transferase. Treatment of MLL-rearranged cell lines with the DOT1L inhibitor selectively inhibits H3K79 methylation and blocks expression of leukemogenic genes. Here we provide expression profiling data of cells treated with DOT1L inhibitor or vehicle control. MV4-11 cells were treated with 3 uM EPZ004777 (DOT1L inhibitor) or vehicle control (0.1% DMSO) for 2, 4 and 6 days. MOLM-13 cells were treated with 3 uM EPZ004777 (DOT1L inhibitor) or vehicle control (0.1% DMSO) for 6 days. For each unique conditon, 3 biological replicates were generated for expression profiling.

2011-07-11 | E-GEOD-29828 | biostudies-arrayexpress

RNAsequencing of DOT1L inhibitor EPZ5676 treated ALDH1+ and ALDH1- cell populations

Project description:Global gene expression profiles obtained after treating cells with DOT1L inhibitor, EPZ5676

2022-01-29 | GSE194434 | GEO

Expression Profiling of Mixed Lineage Leukemia Cells Treated with a Potent Small-Molecule DOT1L Inhibitor

2011-07-11 | GSE29828 | GEO

Expression profiling and H3K79me2 ChIP-seq in Prostate cancer cells treated with DOT1L inhibitor

Project description:Expression profiling and H3K79me2 ChIP-seq in Prostate cancer cells treated with DOT1L inhibitor

| PRJNA559344 | ENA

Transcriptome profiling of castration resistant prostate cancer cells treated with novel AR N-terminal inhibitor

Project description:This study aimed at exploring how would the novel AR N-terminal inhibitor affect the androgen receptor (AR) transcriptome, especially a subset of genes that are uniquely upregulated by AR-V7 in castration resistant prostate cancer cells. We performed next-generation sequencing-based gene expression profiling (RNA-sequencing) on the castration-resistant prostate cancer celll line LNCaP-95. LNCaP-95 expresses high level of endogeneous AR-V7, and also acquired an adaptive shift towards AR-V7-mediated AR signaling activity. Beside regulating the transcription of a subset of canonical wildtype AR genes, AR-V7 also mediates a distinct transcriptional program that is independent of wildtype AR in LNCaP-95. In this experiment, LNCaP-95 cells were treated with vehicle control or the AR-N terminal inhibitor SC912. The subsequent AR transcriptomic change following compound treatment, especially the AR-V7 unique genes were assessed by RNA-seq.

2024-04-30 | GSE253122 | GEO

CDK4/6 inhibitor resistance in prostate cancer

Project description:CDK4/6 kinase inhibitors have shown great promise in clinical trials in various cancer types and have recently entered clinical trial for advanced prostate cancer. Although patients are expected to respond well to this class of drugs, development of resistance in some patients is anticipated. To pre-empt this and study how prostate cancer may evade CDK4/6 inhibition, new resistance models were generated from LNCaP and LAPC4 prostate cancer cells cells by prolonged culturing in presence of 0.5uM palbociclib. A shotgun phosphoproteomics approach was utilized and integrated with RNA sequencing data to unravel the molecular underpinnings of acquired resistance to palbociclib and resultant broad CDK4/6 inhibitor resistance.

2018-05-16 | PXD006561 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data